AngioDynamics' (ANGO) New XL Catheter to Help in PAD Treatment

Company Overview - AngioDynamics, Inc. (ANGO) received FDA clearance for the Auryon XL Catheter, a 225-cm radial access catheter, for use with the Auryon Atherectomy System in treating Peripheral Arterial Disease (PAD) [1] - The Auryon XL Catheter expands access points in atherectomy procedures, potentially reducing access site complications and accelerating patient recovery [1][4] - The catheter is available in sizes of 0.9 mm and 1.5 mm, and may decrease serious bleeding occurrences compared to traditional femoral access [4] - The Auryon XL Catheter is the first non-orbital atherectomy device, setting a new benchmark for laser atherectomy technology [4] - AngioDynamics plans to launch the Auryon XL Catheter in a full market rollout in February 2024 after a limited market launch in January [4][5] Financial Performance - Over the past six months, ANGO's shares have decreased by 31.0%, while the industry declined by 5.0% and the S&P 500 increased by 6.6% [2] Industry Insights - The global atherectomy system market was valued at $621.8 million in 2021 and is projected to grow at a rate of 6.0%, expected to exceed $1.1 billion by 2031 [6] - The growth in the atherectomy system market is driven by the increasing demand for less invasive surgical procedures and the rising prevalence of cardiovascular diseases [6]